Some classes of T2DM therapies—metformin and GLP‐1 agonists—reduce peripheral inflammation and this may contribute to both their anti‐diabetic properties and the reduction in AD incidence reported with their use (Lee & Jun, 2016; Saisho, 2015). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.